Potential immunotargets for Alzheimer's disease treatment strategies

Journal of Alzheimer's Disease

Volumn 33, Issue 2, 2013, Pages 297-312

  Fernández, Patricia L ^a   Britton, Gabrielle B ^a   Rao, K S ^a  

^a INSTITUTO DE INVESTIGACIONES CIENTÍFICAS Y SERVICIOS DE ALTA TECNOLOGÍA   (Panama)

Author keywords

Alzheimer's disease; amyloid ; immunotargets; inflammation; microglia

Indexed keywords

AMYLOID BETA PROTEIN; CD36 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR2; CHEMOTACTIC RECEPTOR FPR2; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PATTERN RECOGNITION RECEPTOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYLOID PLAQUE; CELL ACTIVATION; CYTOKINE PRODUCTION; DRUG TARGETING; IMMUNOREGULATION; IMMUNOTHERAPY; INNATE IMMUNITY; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; UPREGULATION;

EID: 84872472280     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121222     Document Type: Review

References (154)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, JonesE(2011) Alzheimer's disease. Lancet 377, 1019-1031.
2. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer's disease: Identification as the microtubule-associated protein tau. Proc Nat Acad Sci U S A 85, 4051-4055.
3. Busciglio J, Lorenzo A, Yeh J, Yankner BA (1995) -Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879-888.
4. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA (1998) Aging renders the brain vulnerable to amyloid -protein neurotoxicity. Nat Med 4, 827-831. (Pubitemid 28331025)
5. Deshpande A, Mina E, Glabe C, Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26, 6011-6018. (Pubitemid 44318367)
6. Wyss-Coray T (2006) Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat Med 12, 1005-1015. (Pubitemid 44353380)
7. Lih-Fen L, Libuse B, Harold CW, Joseph R (1996) Inflammation, A- deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 55, 1083-1088.
8. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837-1844. (Pubitemid 44049813)
9. Sheng JG, Mrak RE, Griffin WS (1997) Glial-neuronal interactions in Alzheimer disease: Progressive association of IL-1alpha+microglia and S100beta+astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol 56, 285-290. (Pubitemid 27461169)
10. DiPatre PL, Gelman BB (1997) Microglial cell activation in aging and Alzheimer disease: Partial linkagewith neurofibrillary tangle burden in the hippocampus. J Neuropathol Exp Neurol 56, 143-149. (Pubitemid 27461176)
11. Zilka N, Stozicka Z,KovacA, Pilipcinec E, Bugos O, Novak M (2009) Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol 209, 16-25.
12. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351. (Pubitemid 46161268)
13. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM(2005) Lipopolysaccharide-induced inflammation exacerbates Tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25, 8843-8853. (Pubitemid 41384452)
14. Lee DC, Rizer J, Selenica MB, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D (2010) LPSinduced inflammation exacerbates phosphotau pathology in rTg4510 mice. J Neuroinflammation 7, 56.
15. Zilka N, Kazmerova Z, Jadhav S, Neradil P, Madari A, ObetkovaD, Bugos O, NovakM(2012) Who fans the flames of Alzheimer's disease brains? Misfolded tau on the cross road of neurodegenerative and inflammatory pathways. J Neuroinflammation 9, 47.
16. CitronM(2010) Alzheimer's disease: Strategies for disease modification. Nat Rev 9, 387-398.
17. Monsonego A, Weiner HL (2003) Immunotherapeutic approaches to Alzheimer's disease. Science 302, 834-838. (Pubitemid 37339618)
18. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 11, 241-249.
19. Solito E, SastreM(2012) Microglia function in Alzheimer's disease. Front Pharmacol 3, 14.
20. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318. (Pubitemid 40746128)
21. Hanisch UK, Kettenmann H (2007) Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10, 1387-1394. (Pubitemid 350014685)
22. Chen K, Iribarren P, Hu J, Chen J, GongW, Cho EH, Lockett S, Dunlop NM, Wang JM (2006) Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem 281, 3651-3659. (Pubitemid 43845983)
23. El Khoury J, Luster AD (2008) Mechanisms of microglia accumulation in Alzheimer's disease: Therapeutic implications. Trends Pharmacol Sci 29, 626-632.
24. Lehnardt S (2010) Innate immunity and neuroinflammation in the CNS: The role of microglia in Toll-like receptormediated neuronal injury. Glia 58, 253-263.
25. Schwartz M, ShechterR(2010) Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 6, 405-410.
26. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152, 307-317. (Pubitemid 28028071)
27. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451, 720-724. (Pubitemid 351220570)
28. Maezawa I, Zimin PI, Wulff H, Jin LW (2010) Amyloid-protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem 286, 3693-3706.
29. Cameron B, Landreth GE (2010) Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 37, 503-509.
30. Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo Y-M, Roher AE (1996) Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 16, 6021-6037. (Pubitemid 26313978)
31. Grathwohl SA, K?alin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M (2009) Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 12, 1361-1363.
32. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177. (Pubitemid 29327547)
33. Wilcock D, Gordon M, Ugen K, Gottschall P, Dicarlo G, Dickey C, Boyett K, Jantzen P, Connor K, Melachrino J, Hardy J, Morgan D (2001) Number of A- inoculations in APP1PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 20, 731-736. (Pubitemid 34072840)
34. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332. (Pubitemid 39061125)
35. Song M, Xiong J-X, Wang Y-Y, Tang J, Zhang B, Bai Y (2012) VIP enhances phagocytosis of fibrillar beta-amyloid by microglia and attenuates amyloid deposition in the brain of APP/PS1 mice. PLoS One 7, e29790.
36. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D (2001) Intrahippocampal LPS injections reduce A- load in APP+PS1 transgenic mice. Neurobiol Aging 22, 1007-1012. (Pubitemid 34066568)
37. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE (2003) Lipopolysaccharide-inducedneuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 14, 133-145. (Pubitemid 37103187)
38. Hawkes CA, Deng L, Fenili D, Nitz M, McLaurin J (2012) In vivo uptake of -amyloid by non-plaque associated microglia. Curr Alzheimer Res, in press.
39. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489-502. (Pubitemid 43221886)
40. Simard AR, Rivest S (2004) Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J 18, 998-1000. (Pubitemid 39561504)
41. Malm TM, Koistinaho M, P?arepalo M, Vatanen T, Ooka A, Karlsson S, Koistinaho J (2005) Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis 18, 134-142. (Pubitemid 40092904)
42. Stalder AK, Ermini F, Bondolfi L, Krenger W, Burbach GJ, Deller T, Coomaraswamy J, Staufenbiel M, Landmann R, Jucker M (2005) Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci 25, 11125-11132. (Pubitemid 43089557)
43. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM (2007) Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 10, 1538-1543. (Pubitemid 350175883)
44. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Br?uck W, Priller J, Prinz M (2007) Microglia in the adult brain arise from Ly-6ChiCCR2+monocytes only under defined host conditions. Nat Neurosci 10, 1544-1553. (Pubitemid 350175884)
45. Chakraborty S, Kaushik DK, Gupta M, Basu A (2010) Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res 88, 1615-1631.
46. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768-774.
47. Sastre M, Richardson JC, Gentleman SM, Brooks DJ (2011) Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr Alzheimer Res 8, 132-141.
48. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13, 432-438. (Pubitemid 46559828)
49. Izikson L, Klein RS, Charo IF,Weiner HL, LusterAD(2000) Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 192, 1075-1080.
50. Babcock AA, Kuziel WA, Rivest S, Owens T (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 23, 7922-7930. (Pubitemid 37052361)
51. Eltayeb S, Berg AL, Lassmann H, Wallstr?om E, Nilsson M, Olsson T, Ericsson-Dahlstrand A, Sunnemark D (2007) Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: Insight into mechanisms of MOG-induced EAE. J Neuroinflammation 4, 14-26.
52. Naert G, Rivest S (2011) CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 31, 6208-6220.
53. Naert G, Rivest S (2012) Hematopoietic CC-chemokine receptor 2-(CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med 18, 297-313.
54. Meda L, Bernasconi S, Bonaiuto C, Sozzani S, Zhou D, Otvos L, Mantovani A Jr, Rossi F, Cassatella MA (1996) Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. J Immunol 157, 1213-1218.
55. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE (2009) Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 19, 392-398.
56. Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T (2005) Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol 166, 1475-1485. (Pubitemid 40586517)
57. Kiyota T, Yamamoto M, Xion H, Lambert MP, Klein WL, Gendelman HE, RansohoffRM,IkezuT(2009)CCL2accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PloS One 4, e6197.
58. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, HanssonO(2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PloS One 7, e30525.
59. Struthers M, Pasternak A (2010) CCR2 antagonists. Curr Top Med Chem 10, 1278-1298.
60. Giunta B, Rezai-Zadeh K, Tan J (2010) Impact of the CD40-CD40L dyad in Alzheimer's disease. CNS Neurol Disord Drug Targets 9, 149-155.
61. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, MullanM(1999) Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286, 2352-2355. (Pubitemid 30016899)
62. Ponomarev ED, Shriver R, Dittel BN (2006) CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation. J Immunol 176, 1402-1410. (Pubitemid 43134282)
63. Aloisi F, De Simone R, Columba-Cabezas S, Penna G, Adorini L (2000) Functional maturation of adult mouse resting microglia into an APC is promoted by granulocytemacrophage colony-stimulating factor and interaction with Th1 cells. J Immunol 164, 1705-1712. (Pubitemid 30108719)
64. Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5, 1288-1293. (Pubitemid 35417763)
65. Mocali A, Cedrola S, Della Malva N, Bontempelli M, Mitidieri VAM, Bavazzano A, Comolli R, Paoletti F, La Porta CAM (2004) Increased plasma levels of soluble CD40, together with the decrease of TGF-1, as possible differential markers of Alzheimer disease. Exp Gerontol 39, 1555-1561. (Pubitemid 39410556)
66. Calingasan NY, Erdely HA, Altar CA (2002) Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging 23, 31-39. (Pubitemid 34066533)
67. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T (2009) Inflammation in Alzheimer's disease: Amyloid- oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 87, 181-194.
68. Febbraio M, Hajjar DP, Silverstein RL (2001) CD36:Aclass B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108, 785-791. (Pubitemid 32880285)
69. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB (2002) CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to betaamyloid fibrils. Am J Pathol 160, 101-112. (Pubitemid 34052271)
70. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, FreemanMW, LusterAD(2003) CD36 mediates the innate host response to -amyloid. J Exp Med 197, 1657-1666. (Pubitemid 36745341)
71. Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW (2002) A CD36-initiated signaling cascade mediates inflammatory effects of -amyloid. J Biol Chem 277, 47373-47379. (Pubitemid 36163374)
72. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE (2003) A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 23, 2665-2674. (Pubitemid 36418601)
73. Koenigsknecht J, Landreth G (2004) Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci 24, 9838-9846. (Pubitemid 39463564)
74. Bulgarelli I, Tamiazzo L, Bresciani E, Rapetti D, Caporali S, Lattuada D, Locatelli V, Torsello A (2009) Desacyl-ghrelin and synthetic GH-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils. J Neurosci Res 87, 2718-2727.
75. Marleau S, Harb D, Bujold K, Avallone R, Iken K,Wang Y, Demers A, Sirois MG, Febbraio M, Silverstein RL, Tremblay A, Ong H (2005) EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J 19, 1869-1871. (Pubitemid 41598778)
76. Wilkinson K, Boyd JD, Glicksman M, Moore KJ, El Khoury J (2011) A high content drug screen identifies ursolic acid as an inhibitor of amyloid - protein interactions with its receptor CD36. J BiolChem286, 34914-34922.
77. Morisato D, Anderson KV (1994) The spatzle gene encodes a component of the extracellular signaling pathway establishing the dorsal-ventral pattern of the Drosophila embryo. Cell 76, 677-688.
78. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA (1996) The dorsoventral regulatory gene cassette spatzle/toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86, 973-983. (Pubitemid 26336801)
79. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 11, 373-384.
80. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM (1988) The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 141, 547-552.
81. da Silva Correia J, Soldau K, Christen U,Tobias PS, Ulevitch RJ (2001) Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from CD14 to TLR4 and MD-2. J Biol Chem 276, 21129-21135.
82. Fassbender K, Walter S, K?uhl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, BeyreutherK(2004) The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J 18, 203-205.
83. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K (2005) LPS receptor (CD14): A receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 128, 1778-1789. (Pubitemid 41373649)
84. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009) CD14 and toll-like receptors 2 and 4 are required for fibrillar A-stimulated microglial activation. J Neurosci 29, 11982-11992.
85. Carty M, Bowie AG (2011) Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem Pharmacol 81, 825-837.
86. Udan ML, Ajit D, Crouse NR, Nichols MR (2008) Tolllike receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem 104, 524-533. (Pubitemid 350293880)
87. Richard KL, Filali M, Pŕefontaine P, Rivest S (2008) Tolllike receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 28, 5784-5793.
88. Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD, Tahara K, Lalonde R, Fukuchi K (2011) TLR4 mutation reduces microglial activation, increases A- deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation 8, 92.
89. Michaud JP, Richard KL, Rivest S (2012) Hematopoietic MyD88-adaptor protein acts as a natural defense mechanism for cognitive deficits in Alzheimer's disease. Stem Cell Rev 8, 898-904.
90. Yu JT, Mou SM,Wang LZ, Mao CX, Tan L (2011) Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer's disease. J Neuroinflammation 8, 136.
91. Wang LZ, Yu JT, Miao D,Wu ZC, Zong Y,Wen CQ, Tan L (2011) Genetic association of TLR4/11367 polymorphism with late-onset Alzheimer's disease in a Han Chinese population. Brain Res 1381, 202-207.
92. Stewart CR, Stuart LM,Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11, 155-161.
93. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K (2006) Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 129, 3006-3019. (Pubitemid 44684521)
94. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K (2008) Tolllike receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 5, 23.
95. LeY, Li B, GongW, ShenW, Hu J, Dunlop NM, Oppenheim JJ,Wang JM (2000) Novel pathophysiological role of classical chemotactic peptide receptors and their communications with chemokine receptors. Immunol Rev 177, 185-194.
96. Lorton D, Schaller J, Lala A, De Nardin E (2000) Chemotactic-like receptors and A- peptide induced responses in Alzheimer's disease. Neurobiol Aging 21, 463-473. (Pubitemid 30349117)
97. Cui YH, LeY, GongW, Proost P,VanDammeJ, MurphyWJ, Wang JM (2002) Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. J Immunol 168, 434-442. (Pubitemid 34014146)
98. Yazawa H, Yu Z-X, Takeda, Le Y, Gong W, Ferrans VJ, Oppenhein JJ, Li CCH,Wang JM (2001) - Amyloid peptide (A-42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J 15, 2454-2462.
99. Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, Shen W, Dunlop NM, Gao J-L, Murphy PM, Oppenheim JJ,Wang JM (2001) Amyloid beta 42 activates a G-proteincoupled chemoattractant receptor, FPR-like-1. J Neurosci 21, RC123.
100. Merson TD, Binder MD, Kilpatrick TJ (2010) Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. Neuromol Med 12, 99-132.
101. Tansey MG, Wyss-Coray T (2008) Cytokines in CNS inflammation and disease. In Central Nervous System Diseases and Inflammation, Lane TE, Carson M, Bergman C, Wyss-Coray T, eds. Springer, Heidelberg, pp. 59-106.
102. Huising MO, Stet RJM, Savelkoul HFJ, Verburg-van Kemenade BML (2004) The molecular evolution of the interleukin-1 family of cytokines; IL-18 in teleost fish. Dev Comp Immunol 28, 395-413. (Pubitemid 38177444)
103. Legos JJ, Whitmore RG, Erhardt JA, Parsons AA, Tuma RF, Barone FC (2000) Quantitative changes in interleukin proteins following focal stroke in the rat. Neurosci Lett 282, 189-192. (Pubitemid 30136459)
104. Dinarello CA (2007) A signal for the caspase-1 inflammasome free of TLR. Immunity 26, 383-385. (Pubitemid 46603007)
105. Nicoll JAR, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, MossT, GriffinWS(2000) Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47, 365-368. (Pubitemid 30141847)
106. GriffinWST, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in down syndrome and Alzheimer disease. Proc Nat Acad Sci U S A 86, 7611-7615. (Pubitemid 19254506)
107. Lorton D, Kocsis J-M, King L, Madden K, Brunden KR (1996) -Amyloid induces increased release of interleukin-1- from lipopolysaccharide-activated human monocytes J Neuroimmunol 67, 21-29.
108. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9, 857-865.
109. Basu A, Krady JK, Levison SW (2004) Interleukin-1: A master regulator of neuroinflammation. J Neurosci Res 78, 151-156. (Pubitemid 39313786)
110. Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5, 629-640. (Pubitemid 41113194)
111. Griffin WST (2006) Inflammation and neurodegenerative diseases. Am J Clin Nutr 83, 470S-474S. (Pubitemid 44713221)
112. Griffin WST, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE (1998) Glial-neuronal interactions in Alzheimer's disease: The potential role of a 'cytokine cycle' in disease progression. Brain Pathol 8, 65-72. (Pubitemid 28055765)
113. Craft JM, Watterson DM, Hirsch E, Van Eldik LJ (2005) Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human -amyloid. J Neuroinflammation 2, 15.
114. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal -catenin pathway function in an Alzheimer's disease model. J Immunol 187, 6539-6549.
115. Shaftel SS, Griffin WST, O'Banion MK (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: An evolving perspective. J Neuroinflammation 5, 7.
116. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK (2007) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117, 1595-1604. (Pubitemid 46871344)
117. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN (2004) Time-dependent reduction in A- levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 190, 245-253. (Pubitemid 39335723)
118. Matousek SB, Ghosh S, Shaftel SS, Kyrkanides S, Olschowka JA, O'Banion MK (2012) Chronic IL-1-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration. J Neuroimmune Pharmacol 7, 156-164.
119. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LNG (1999) Translation of the Alzheimer amyloid precursor proteinmRNAis up-regulated by interleukin-1 through 5-untranslated region sequences. J Biol Chem 274, 6421-6431. (Pubitemid 29111057)
120. Bandyopadhyay S, Hartley DM, Cahill CM, Lahiri DK, Chattopadhyay N, Rogers JT (2006) Interleukin-1- stimulates non-amyloidogenic pathway by -secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J Neurosci Res 84, 106-118. (Pubitemid 44023067)
121. Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y, Murayama S, Endo T, Sakaguchi G, Kato A, Kitazume S, Hashimoto Y (2008) Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: Resulting decrease in Abeta production. J Neurochem 104, 1387-1393. (Pubitemid 351293352)
122. LiaoY-F,Wang B-J, Cheng H-T,Kuo L-H,WolfeMS(2004) Tumor necrosis factor-, interleukin-1, and interferon-stimulate -secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 279, 49523-49532.
123. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 117, 244-279.
124. Tobinick E (2009) Tumour necrosis factor modulation for treatment of Alzheimer's disease rationale and current evidence. CNS Drugs 23, 713-725.
125. Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Camm̀a C, Lio D, Caruso C (2009) Systematic reviewby meta-analyses on the possible role of TNF- polymorphisms in association with Alzheimer's disease. Brain Res Rev 61, 60-68.
126. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T (2007) Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170, 680-692. (Pubitemid 47339404)
127. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B (1999) TNF- plus IFN- induce the production of Alzheimer -amyloid peptides and decrease the secretion of APPs. FASEB J 13, 63-68. (Pubitemid 29038275)
128. Combs CK, Karlo JC, Kao S-C, Landreth GE (2001) -amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21, 1179-1188. (Pubitemid 32128763)
129. Haviv R, Stein R (1998) The intracellular domain of p55 tumor necrosis factor receptor induces apoptosis which requires different caspases in naive and neuronal PC12 cells. J Neurosci Res 52, 380-389. (Pubitemid 28259105)
130. Floden AM, Li S, Combs CK (2005) -amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor - and NMDA receptors. J Neurosci 25, 2566-2575. (Pubitemid 40365168)
131. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y (2007) Deletion of tumor necrosis factor death receptor inhibits amyloid - generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 178, 829-841. (Pubitemid 47347367)
132. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ (2008) Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3×Tg-AD mice. Am J Pathol 173, 1768-1782.
133. Mbebi C, Gonźalez de Aguilar J-L, Śee V, Dupuis L, Frossard N, Mercken L, Pradier L, Larmet Y, Loeffler J-P (2005) Antibody-bound -amyloid precursor protein stimulates the production of tumor necrosis factor- and monocyte chemoattractant protein-1 by cortical neurons. Neurobiol Dis 19, 129-141. (Pubitemid 40544730)
134. Medeiros R, Prediger RDS, Passos GF, Pandolfo P, Duarte FS, Franco JL, Dafre AL, Giunta GD, Figueiredo CP, Takahashi RN, Campos MM, Calixto JB (2007) Connecting TNF- signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: Relevance for the behavioral and synaptic deficits induced by amyloid - protein. J Neurosci 27, 5394-5404. (Pubitemid 46790177)
135. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang YD, Xu J (2010) Anti-TNF- reduces amyloid plaques and tau phosphorilation and induces CD11c-positive dendritic-like cel in the APP/PS1 transgenic mouse brains. Brain Res 1368, 239-247.
136. Tobinick E (2009) Perispinal etanercept for neuroinflammatory disorders. Drug Dis Today 14, 168-177.
137. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB (1995) Altered expression of transforming growth factor-in Alzheimer's disease. Neurology 45, 1561-1569.
138. Flanders KC, Ren RF, Lippa CF (1998) Transforming growth factor-s in neurodegenerative disease. Prog Neurobiol 54, 71-85.
139. Lesńe S, Docagne F, Gabriel C, Liot G, Lahiri DK, Búee L, Plawinski L, Delacourte A, MacKenzie ET, Buisson A, Vivien D (2003) Transforming growth factor-1 potentiates amyloid- generation in astrocytes and in transgenic mice. J Biol Chem 278, 18408-18418.
140. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L (1997) Amyloidogenic role of cytokine TGF-1 in transgenic mice and in Alzheimer's disease. Nature 389, 603-606.
141. Peress NS, Perillo E (1995) Differential expression of TGF-1, 2 and 3 isotypes in Alzheimer's disease: A comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol 54, 802-811.
142. Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E (2000) Chronic overproduction of transforming growth factor-1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol 156, 139-150.
143. Grammas P, Ovase R (2002) Cerebrovascular transforming growth factor- contributes to inflammation in the Alzheimer's disease brain. Am J Pathol 160, 1583-1587. (Pubitemid 34525638)
144. Wyss-Coray T, Lin C, Yan F, Yu G-Q, Rohde M, Mcconlogue L, Masliah E, Mucke L (2001) TGF-1 promotes microglial amyloid- clearance and reduces plaque burden in transgenic mice. Nat Med 7, 612-618.
145. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA (2008) Blocking TGF-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14, 681-687. (Pubitemid 351809551)
146. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, Mucke L, Masliah E, Wyss-Coray T (2006) Deficiency in neuronal TGF- signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest 116, 3060-3069. (Pubitemid 44684491)
147. Hashimoto Y, Nawa M, Chiba T, Aiso S, Nishimoto I, MatsuokaM(2006) Transforming growth factor -2 autocrinally mediates neuronal cell death induced by amyloid-. J Neurosci Res 83, 1039-1047.
148. Hashimoto Y, Chiba T, Yamada M, Nawa M, Kanekura K, Suzuki H, Terashita K, Aiso S, Nishimoto I, Matsuoka M (2005) Transforming growth factor -2 is a neuronal deathinducing ligand for amyloid- precursor protein. Mol Cell Biol 25, 9304-9317. (Pubitemid 41507832)
149. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE (1991) Prevention and treatment of chronic relapsing experimental allergy encephalomyelitis by transforming growth factor-. J Immunol 146, 3012-3017.
150. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE (2001) In-vivo measurement of activated microglia in dementia. Lancet 358, 461-467. (Pubitemid 32769854)
151. Hauss-Wegrzyniak B, Galons JP, Wenk GL (2000) Quantitative volumetric analysis of brain magnetic resonance imaging from rat with chronic neuroinflammation and correlation with histology. Exp Neurol 165, 347-354.
152. Liu X,Wu Z, HayashiY, NakanishiH(2012) Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation. Neuroscience 216, 133-142.
153. Braak H, Del Tredici-Braak K (2012) Evolutional aspects of Alzheimer's disease pathogenesis. J Alzheimers Dis, doi: 10.3233/JAD-2012-129029.
154. Price JL, McKeel DW Jr, Buckles VD, Roec CM, Xiong C, Grundmane M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kayem J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC (2009) Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30, 1026-1036.